RecruitingPhase 4NCT06814938
A Study of a Novel Precision Medicine Approach For Obesity
A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
Sponsor
Mayo Clinic
Enrollment
135 participants
Start Date
Feb 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- \- Obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g., controlled hypertension).
Exclusion Criteria9
- Weight changes greater than 3% in the previous 3 months
- History of bariatric surgery including lap band and bariatric endoscopy
- Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
- Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
- Any contraindication to FDA-approved GLP1R agonists
- A person who is pregnant or wanting to become pregnant
- Once the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
- A family member who is enrolled in this study.
- Principal Investigator Discretion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSemaglutide
2.4 mg subcutaneous weekly
DRUGPlacebo
Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06814938
Related Trials
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT0722568643 locations
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT011434543 locations
Early Tracking of Childhood Health Determinants (ETCHED) Study
NCT034818291 location
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
NCT019277831 location
First in Human Study in Subjects With Obesity, But Otherwise Healthy
NCT062522201 location